Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 20/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 17/20 | 0.80 |
| ▸ | CCND1 | P24385 | 17/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515010 | 0.92 | CCNE2 (0.84) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL7998067 | 0.90 | CCNE2 (0.82) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4023838 | 0.89 | CCNE2 (1.00) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4024263 | 0.88 | CCNE2 (1.00) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL7987273 | 0.88 | CCNE2 (0.78) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4027362 | 0.87 | CCNE2 (1.00) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4026857 | 0.86 | CCNE2 (0.81) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4025029 | 0.86 | CCNE1 (0.85) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL8003472 | 0.86 | CCNE2 (0.75) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL5514173 | 0.85 | CCNE2 (0.74) | CCNE2CCNE1CDK2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1071668-B1 | 5-AMINOINDENO[1,2-C]PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1071668-B1 | 5-AMINOINDENO[1,2-C]PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-06-03 | — | — | EP | disclosed |
| US-6413957-B1 | CYCLIN DEPENDANT KINASES INHIBITORS; CONTROLLING CELL GROWTH AND DIFFERENTIATION; CANCER, PSORIASIS, LEUKOCYTE IMMUNO-LOGICAL DISORDERS, RESTINOSIS AND OTHER SMOOTH MUSCLE CELL DISORDERS | BRISTOL-MYERS SUIBB PHARMA COMPANY | 2002-07-02 | — | — | US | disclosed |